Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma

Alessandro Morabito, Massimo Fanelli, Guido Carillio, Domenico Gattuso, Roberta Sarmiento, Giampietro Gasparini

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Thalidomide shows antiangiogenic activity and it has been successfully employed in various tumors. Considering the poor therapeutic options for glioblastoma and the role of angiogenesis in malignant glioma cells growth, we investigated the therapeutic activity of thalidomide in patients affected by recurrent glioblastoma. Inclusion criteria were: recurrent glioblastoma pretreated with surgery and radiotherapy, age ≥18 years, adequate performance status, hematological, renal, and hepatic functions. Exclusion criteria included severe underlying diseases, neuropathy or concurrent radiotherapy. Eighteen patients entered the study, 17 of whom were assessable for toxicity and response. Most of patients were pretreated with chemotherapy (77.8%). Thalidomide was well tolerated: the most common side effects were constipation (76.5% of patients), somnolence (47%), and peripheral neuropathy (11.8%). One minimal response (MR) and 8 stable disease (SD) were observed, with an overall clinical benefit of 52.9%. Median time to progression and median overall survival (OS) for responders was 25 weeks (range 12-40) and 36 weeks (range 16-64), respectively. In conclusion, thalidomide induces modest side effects and it may be considered a valid therapeutic option for patients with recurrent glioblastoma.

Original languageEnglish
Pages (from-to)93-95
Number of pages3
JournalOncology Reports
Volume11
Issue number1
Publication statusPublished - Jan 2004

Fingerprint

Thalidomide
Glioblastoma
Radiotherapy
Therapeutics
Peripheral Nervous System Diseases
Constipation
Glioma
Kidney
Drug Therapy
Survival
Liver
Growth
Neoplasms

Keywords

  • Recurrent glioblastoma
  • Thalidomide
  • Therapeutic options

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Morabito, A., Fanelli, M., Carillio, G., Gattuso, D., Sarmiento, R., & Gasparini, G. (2004). Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. Oncology Reports, 11(1), 93-95.

Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. / Morabito, Alessandro; Fanelli, Massimo; Carillio, Guido; Gattuso, Domenico; Sarmiento, Roberta; Gasparini, Giampietro.

In: Oncology Reports, Vol. 11, No. 1, 01.2004, p. 93-95.

Research output: Contribution to journalArticle

Morabito, A, Fanelli, M, Carillio, G, Gattuso, D, Sarmiento, R & Gasparini, G 2004, 'Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma', Oncology Reports, vol. 11, no. 1, pp. 93-95.
Morabito, Alessandro ; Fanelli, Massimo ; Carillio, Guido ; Gattuso, Domenico ; Sarmiento, Roberta ; Gasparini, Giampietro. / Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. In: Oncology Reports. 2004 ; Vol. 11, No. 1. pp. 93-95.
@article{8fa230e694b640aa9e60b72b66713447,
title = "Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma",
abstract = "Thalidomide shows antiangiogenic activity and it has been successfully employed in various tumors. Considering the poor therapeutic options for glioblastoma and the role of angiogenesis in malignant glioma cells growth, we investigated the therapeutic activity of thalidomide in patients affected by recurrent glioblastoma. Inclusion criteria were: recurrent glioblastoma pretreated with surgery and radiotherapy, age ≥18 years, adequate performance status, hematological, renal, and hepatic functions. Exclusion criteria included severe underlying diseases, neuropathy or concurrent radiotherapy. Eighteen patients entered the study, 17 of whom were assessable for toxicity and response. Most of patients were pretreated with chemotherapy (77.8{\%}). Thalidomide was well tolerated: the most common side effects were constipation (76.5{\%} of patients), somnolence (47{\%}), and peripheral neuropathy (11.8{\%}). One minimal response (MR) and 8 stable disease (SD) were observed, with an overall clinical benefit of 52.9{\%}. Median time to progression and median overall survival (OS) for responders was 25 weeks (range 12-40) and 36 weeks (range 16-64), respectively. In conclusion, thalidomide induces modest side effects and it may be considered a valid therapeutic option for patients with recurrent glioblastoma.",
keywords = "Recurrent glioblastoma, Thalidomide, Therapeutic options",
author = "Alessandro Morabito and Massimo Fanelli and Guido Carillio and Domenico Gattuso and Roberta Sarmiento and Giampietro Gasparini",
year = "2004",
month = "1",
language = "English",
volume = "11",
pages = "93--95",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma

AU - Morabito, Alessandro

AU - Fanelli, Massimo

AU - Carillio, Guido

AU - Gattuso, Domenico

AU - Sarmiento, Roberta

AU - Gasparini, Giampietro

PY - 2004/1

Y1 - 2004/1

N2 - Thalidomide shows antiangiogenic activity and it has been successfully employed in various tumors. Considering the poor therapeutic options for glioblastoma and the role of angiogenesis in malignant glioma cells growth, we investigated the therapeutic activity of thalidomide in patients affected by recurrent glioblastoma. Inclusion criteria were: recurrent glioblastoma pretreated with surgery and radiotherapy, age ≥18 years, adequate performance status, hematological, renal, and hepatic functions. Exclusion criteria included severe underlying diseases, neuropathy or concurrent radiotherapy. Eighteen patients entered the study, 17 of whom were assessable for toxicity and response. Most of patients were pretreated with chemotherapy (77.8%). Thalidomide was well tolerated: the most common side effects were constipation (76.5% of patients), somnolence (47%), and peripheral neuropathy (11.8%). One minimal response (MR) and 8 stable disease (SD) were observed, with an overall clinical benefit of 52.9%. Median time to progression and median overall survival (OS) for responders was 25 weeks (range 12-40) and 36 weeks (range 16-64), respectively. In conclusion, thalidomide induces modest side effects and it may be considered a valid therapeutic option for patients with recurrent glioblastoma.

AB - Thalidomide shows antiangiogenic activity and it has been successfully employed in various tumors. Considering the poor therapeutic options for glioblastoma and the role of angiogenesis in malignant glioma cells growth, we investigated the therapeutic activity of thalidomide in patients affected by recurrent glioblastoma. Inclusion criteria were: recurrent glioblastoma pretreated with surgery and radiotherapy, age ≥18 years, adequate performance status, hematological, renal, and hepatic functions. Exclusion criteria included severe underlying diseases, neuropathy or concurrent radiotherapy. Eighteen patients entered the study, 17 of whom were assessable for toxicity and response. Most of patients were pretreated with chemotherapy (77.8%). Thalidomide was well tolerated: the most common side effects were constipation (76.5% of patients), somnolence (47%), and peripheral neuropathy (11.8%). One minimal response (MR) and 8 stable disease (SD) were observed, with an overall clinical benefit of 52.9%. Median time to progression and median overall survival (OS) for responders was 25 weeks (range 12-40) and 36 weeks (range 16-64), respectively. In conclusion, thalidomide induces modest side effects and it may be considered a valid therapeutic option for patients with recurrent glioblastoma.

KW - Recurrent glioblastoma

KW - Thalidomide

KW - Therapeutic options

UR - http://www.scopus.com/inward/record.url?scp=3543132551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543132551&partnerID=8YFLogxK

M3 - Article

C2 - 14654909

AN - SCOPUS:3543132551

VL - 11

SP - 93

EP - 95

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -